September 3, 2026 New coalition brings together organizations from across the mitochondrial disease community to accelerate research funding, advance patient-centered legislation, and foster a responsive regulatory environment for new therapies. […]
Pretzel Therapeutics Advances PX578 into Phase 2 Study in Individuals Living with POLG-mediated Primary Mitochondrial Disease Following FDA Clearance of IND
August 25, 2026 PX578, a potentially disease-modifying, first-in-class investigational medicine cleared to start clinical trials in patients Initiation of Phase 2 Trial in POLG-PMD (POLG Disease) Planned for late 2026 […]
Mighty Therapeutics, Formerly Stealth BioTherapeutics, Announces New Name Honoring the Mitochondrial Disease Community
June 16, 2026 NEEDHAM, Mass., June 16, 2026 — Stealth BioTherapeutics Holdings Inc., a commercial-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for rare and […]
Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease
April 16, 2026 NOTES TO EDITORSAbout KhondrionKhondrion is a late-stage clinical biopharmaceutical company focused on developing therapies forpatients with primary mitochondrial disease (PMD). Its lead asset, sonlicromanol, is a brain-penetrantredox […]
Navigating the FDA’s Complete Response Letter and identifying a path forwardfor SL1009 (DCA).
March 31, 2026 Dear Members of the PDCD Community, We are deeply grateful for your support and advocacy throughout this process, particularly aswe have worked to navigate the FDA’s Complete […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 34
- Next Page »












